Literature DB >> 12092045

Control of Chagas disease.

.   

Abstract

Chagas disease occurs throughout Mexico and central and southern America and continues to pose a serious threat to health in many countries of the region. People infected with the trypanosome parasite may suffer cardiac, gastrointestinal, or neurological damage, although disease manifestations vary widely from one endemic area to another. In the past decade, control programmes in several endemic countries have proved remarkably successful; interruption of disease transmission has been achieved in some and is imminent in others, leading to a substantial reduction in the incidence of Chagas disease in Latin America. However, 8-9 million people in Mexico and the Andean and central American countries are infected with the parasite and 25 million remain at risk, emphasizing the need to sustain and extend control strategies. This report of a WHO Expert Committee reviews current knowledge of Chagas disease and its pathogenesis, discusses the causative parasite, the triatomine vectors, and the natural reservoirs of infection, and considers the epidemiology and incidence trends of the disease. Prevention and control strategies are described, as are the various formal initiatives for interruption of disease transmission. The report concludes by identifying priorities for research and offering guidance for the planning, implementation, and strengthening of national control programmes.

Entities:  

Mesh:

Year:  2002        PMID: 12092045

Source DB:  PubMed          Journal:  World Health Organ Tech Rep Ser        ISSN: 0512-3054


  163 in total

1.  Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera.

Authors:  Cristina Riera; Mireia Verges; Laura Iniesta; Roser Fisa; Montserrat Gállego; Silvia Tebar; Montserrat Portús
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

Review 2.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Chagas disease 101.

Authors:  Julie Clayton
Journal:  Nature       Date:  2010-06-24       Impact factor: 49.962

Review 4.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

5.  Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.

Authors:  Milagros Corrales; Rubén Cardozo; María Asunción Segura; Julio A Urbina; Miguel Angel Basombrío
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

Authors:  Irene Losada Galván; Olaya Madrid Pascual; Juan María Herrero-Martínez; Ana Pérez-Ayala; Manuel Lizasoain Hernández
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

7.  Identification and characterization of microsatellite markers in the Chagas disease vector Triatoma infestans (Heteroptera: Reduviidae).

Authors:  P L Marcet; T Lehmann; G Groner; R E Gürtler; U Kitron; E M Dotson
Journal:  Infect Genet Evol       Date:  2006-01       Impact factor: 3.342

8.  Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?

Authors:  D M Vitelli-Avelar; R Sathler-Avelar; R L Massara; J D Borges; P S Lage; M Lana; A Teixeira-Carvalho; J C P Dias; S M Elói-Santos; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

9.  Parasitic colitides.

Authors:  Joel E Goldberg
Journal:  Clin Colon Rectal Surg       Date:  2007-02

10.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.